What Are the Challenges in Using Mutation Burden as a Biomarker?
Despite its potential, there are several challenges in using mutation burden as a biomarker. One major challenge is the variability in TMB assessment methods, which can lead to inconsistent results. Additionally, not all high-TMB tumors respond to immunotherapy, indicating that other factors also play a role in determining treatment efficacy. Standardization of measurement techniques and further research are needed to fully realize the potential of TMB as a biomarker.
